# 270 ‒ Journal club with Andrew Huberman: metformin, power of belief, & how to read scientific papers

**Channel:** Peter Attia MD
**Upload Date:** 2023-09-11
**URL:** https://www.youtube.com/watch?v=boyTPdYJArs
**Duration:** 131 minutes

## Description

Watch the full episode and view show notes here: https://bit.ly/3PylTGR
Become a member to receive exclusive content: https://peterattiamd.com/subscribe/
Sign up to receive Peter's email newsletter: https://peterattiamd.com/newsletter/

Andrew Huberman, Professor of Neurobiology at Stanford University and host of the Huberman Lab podcast, joins us in a special journal club episode. Peter and Andrew each present a recent paper that sparked their interests, delving into the findings, dissecting their significance, discussing potential confounders and limitations, and exploring remaining questions. Importantly, they share their methodologies for comprehending research studies, providing valuable insights for listeners to navigate this process independently. Peter presents an epidemiological study reevaluating a noteworthy metformin result that intrigued the anti-aging community, leading to discussions on metformin's geroprotective potential (or lack thereof) and the current lack of aging biomarkers. Andrew introduces a paper examining how our beliefs about the medications we take influence their biological effects, distinguishing the "belief effect" from a placebo effect and highlighting its exciting implications for the future.

We discuss:
0:00:00 - Intro
0:00:10 - The motivation behind this journal club conversation
0:06:33 - Why Peter chose a paper on metformin, how metformin works, and why it generated excitement as a longevity-enhancing agent
0:13:45 - Defining insulin resistance and its underlying causes
0:19:28 - Metformin as a first-line treatment for type 2 diabetes, and Peter’s evolving interest in metformin as a geroprotective drug
0:22:20 - Defining the term “geroprotection”
0:23:31 - The 2014 study that got the anti-aging community interested in metformin
0:30:43 - Peter presents the 2022 paper that repeats the analytical approach from the 2014 Bannister study
0:37:30 - Greater mortality in the metformin group: how results differed between the 2022 paper and the 2014 paper
0:49:20 - Understanding statistical significance, statistical power, sample size, and why epidemiology uses enormous cohorts
0:54:18 - Interpreting the hazard ratios from the 2022 metformin study, and the notable takeaways from the study
1:06:10 - Drugs that may extend lifespan, why Peter stopped taking metformin, and a discussion of caloric restriction
1:18:29 - Current thoughts on the use of metformin for longevity
1:20:05 - Could there be any longevity benefit to short periods of caloric restriction?
1:23:53 - Peter and Andrew’s process for reading scientific papers
1:30:05 - The biological effects of belief, and how “belief effects” differ from placebo effects
1:37:19 - The neurobiology of nicotine: a precursor conversation before delving into the paper Andrew chose
1:43:00 - Andrew presents a paper that demonstrates the impact of belief
1:52:02 - Analyzing the fascinating results of the Perl paper
2:00:45 - Exciting implications of the findings about “belief effects” 

--------
About:

The Peter Attia Drive is a deep-dive podcast focusing on maximizing longevity, and all that goes into that from physical to cognitive to emotional health. With over 70 million episodes downloaded, it features topics including exercise, nutritional biochemistry, cardiovascular disease, Alzheimer’s disease, cancer, mental health, and much more.

Peter Attia is the founder of Early Medical, a medical practice that applies the principles of Medicine 3.0 to patients with the goal of lengthening their lifespan and simultaneously improving their healthspan. 

Learn more: https://peterattiamd.com

Connect with Peter on:
Facebook: http://bit.ly/PeterAttiaMDFB
Twitter: http://bit.ly/PeterAttiaMDTW
Instagram: http://bit.ly/PeterAttiaMDIG

Subscribe to The Drive:
Apple Podcast: http://bit.ly/TheDriveApplePodcasts
Overcast: http://bit.ly/TheDriveOvercast
Spotify: http://bit.ly/TheDriveSpotify
Google Podcasts: http://bit.ly/TheDriveGoogle

Disclaimer: This podcast is for general informational purposes only and does not constitute the practice of medicine, nursing, or other professional healthcare services, including the giving of medical advice. No doctor-patient relationship is formed. The use of this information and the materials linked to this podcast is at the user's own risk. The content on this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard or delay in obtaining medical advice for any medical condition they have, and they should seek the assistance of their healthcare professionals for any such conditions. I take conflicts of interest very seriously. For all of my disclosures and the companies I invest in or advise, please visit my website where I keep an up-to-date and active list of such companies. For a full list of our registered and unregistered trademarks, trade names, and service marks, please review our Terms of Use: https://peterattiamd.com/terms-of-use/

## AI Summary

Here's my comprehensive analysis of this episode of The Drive podcast:

1. **Executive Summary**:
This episode features Peter Attia and Andrew Huberman discussing two major papers: one on metformin's effects on mortality in diabetics, and another on belief effects and nicotine. The discussion covers detailed analysis of research methodology, statistical interpretation, and practical implications. The conversation demonstrates how to critically analyze scientific papers and highlights the importance of understanding both the strengths and limitations of different research approaches.

2. **Key Medical/Scientific Points**:
- Metformin inhibits complex one of the mitochondria [08:31]
- Type 2 diabetes typically shortens lifespan by 6 years [28:11]
- Banister study showed 15% reduction in mortality with metformin over 2.8 years [28:43]
- Keys study showed higher mortality in metformin users vs non-diabetic controls [54:57]
- Belief effects can alter physiological responses to drugs [1:32:35]

3. **Health Optimization Tips**:

Universal recommendations:
- Regular exercise is crucial for insulin sensitivity [1:16:37]
- Sleep deprivation significantly impacts insulin resistance [1:16:45]

Context-specific recommendations:
- Metformin may not be beneficial for non-diabetic, exercise-active individuals [1:19:55]
- Consider berberine as an alternative to metformin for glucose management [1:11:29]

4. **Supplements & Medications**:

Medications discussed:
- Metformin: 2g/day mentioned as full dose [21:20]
- GLP-1 agonists (e.g., Ozempic) [26:45]
- SGLT2 inhibitors [1:15:13]

Warnings:
- Metformin can increase lactate levels at rest [1:08:13]
- Initial metformin side effects include nausea [21:42]

5. **Exercise & Movement**:
- Zone 2 training mentioned with lactate testing [1:08:50]
- Exercise is crucial for insulin sensitivity management [1:16:37]

6. **Nutrition & Diet**:
- Energy balance is more important than specific macronutrient ratios [1:16:55]
- Unprocessed or minimally processed foods recommended [1:18:01]

7. **Biomarkers & Testing**:
- Resting lactate should be below 1 mmol/L [1:08:13]
- Fasting glucose measurements discussed [1:14:29]

8. **References & Resources**:
- Banister study (2014) on metformin and mortality [28:43]
- Keys study on metformin mortality in Danish population [54:57]
- ITP (Interventions Testing Program) studies mentioned [1:06:02]

9. **Notable Quotes**:
"The difference between being metabolically healthy and having profound type 2 diabetes is one teaspoon of glucose in your bloodstream" [09:47]

10. **Follow-up Questions**:
- What is the optimal timing and dosing of berberine?
- How does belief effect impact other commonly used medications?
- What are the implications of belief effects for clinical practice?

Would you like me to expand on any of these sections?
